The in-vitro diagnostics instruments market size has grown strongly in recent years. It will grow from $61.09 billion in 2025 to $67.18 billion in 2026 at a compound annual growth rate (CAGR) of 10%. The growth in the historic period can be attributed to rising prevalence of chronic diseases, increasing hospital lab infrastructure, advances in diagnostic reagents, growing awareness for early disease detection, government healthcare initiatives.
The in-vitro diagnostics instruments market size is expected to see rapid growth in the next few years. It will grow to $99.44 billion in 2030 at a compound annual growth rate (CAGR) of 10.3%. The growth in the forecast period can be attributed to technological advancements in molecular diagnostics, growth of personalized medicine, integration of AI in diagnostics, expansion of emerging markets healthcare, demand for home-based diagnostic devices. Major trends in the forecast period include point-of-care testing expansion, personalized diagnostics, rapid molecular testing adoption, remote patient monitoring integration, miniaturized lab instruments.
The rising prevalence of chronic and lifestyle related diseases is expected to enhance the growth of the in vitro diagnostics instruments market in the coming years. Chronic and lifestyle related diseases refer to long term health conditions primarily influenced by daily habits, behaviors, and environmental factors, such as heart disease, diabetes, obesity, and certain cancers. The incidence of these diseases is increasing due to sedentary lifestyles and unhealthy dietary habits. In vitro diagnostics instruments are experiencing higher demand as the growing burden of chronic and lifestyle related diseases encourages companies to adopt early detection and monitoring tools for improved disease management. For example, in 2024, according to the American Action Forum, a U.S. based non profit, center right think tank, chronic diseases remain a major public health concern in the United States, with nearly 60 percent of adults living with at least one condition, 40 percent managing multiple conditions, and prevalence expected to nearly double by 2050. Furthermore, the chronic disease treatment market is projected to reach approximately 38.02 billion dollars by 2034, up from 9.74 billion dollars in 2025. Therefore, the rising prevalence of chronic and lifestyle related diseases is enhancing the growth of the in vitro diagnostics instruments market.
Prominent companies operating in the in-vitro diagnostics instruments market are focusing on developing advanced technologies, such as digital polymerase chain reaction (dPCR) systems, to achieve highly precise and sensitive nucleic acid quantification for next-generation diagnostics. Digital polymerase chain reaction (dPCR) systems are sophisticated diagnostic instruments that quantify DNA or RNA molecules by dividing samples into thousands of individual reactions, allowing for exceptional accuracy and sensitivity in detection. For example, in September 2024, QIAGEN N.V., a Netherlands-based biotechnology company, introduced the QIAcuityDx Digital PCR System, expanding its dPCR portfolio into clinical diagnostics with a primary focus on oncology testing. This fully integrated and automated system is specifically designed for clinical use, featuring a cartridge-based workflow that minimizes manual handling. Equipped with automated analysis and reporting software, the QIAcuityDx enables rapid and precise detection of genetic biomarkers for cancer diagnosis and therapy monitoring, reducing operator involvement while ensuring reliable and reproducible results.
In January 2025, Fremman Ltd., a UK-based investment company, acquired a majority stake in DIESSE Diagnostica Senese S.p.A. for an undisclosed amount. Through this acquisition, Fremman Ltd aims to expand DIESSE Diagnostica Senese's international presence, strengthen its leadership in specialty in vitro diagnostics, and support ongoing innovation to advance global diagnostic capabilities and improve patient outcomes. DIESSE Diagnostica Senese S.p.A. is an Italy-based medical equipment company that provides in vitro diagnostic instruments.
Major companies operating in the in-vitro diagnostics instruments market are F. Hoffmann-La Roche Ltd, Danaher Corporation, Abbott Laboratories, Thermo Fisher Scientific, Siemens Healthineers AG, Becton Dickinson and Company, Sysmex Corporation, Bio-Rad Laboratories Inc, Agilent Technologies, Hologic Inc, Qiagen N.V., Illumina Inc, Ortho Clinical Diagnostics, Beckman Coulter Inc, Mindray Medical International Limited, Horiba Ltd, Randox Laboratories Ltd, DiaSorin S.p.A., Werfen S.A., Trinity Biotech plc.
North America was the largest region in the in-vitro diagnostics instruments market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the in-vitro diagnostics instruments market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the in-vitro diagnostics instruments market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Tariffs are impacting the in-vitro diagnostics instruments market by increasing costs of imported reagents, analyzers, and precision components, particularly affecting molecular diagnostics and clinical chemistry segments. Asia-Pacific manufacturing hubs such as China and India are most impacted, causing supply chain disruptions and higher device prices. However, tariffs are encouraging local manufacturing investments, which could improve domestic production capabilities and reduce long-term dependency on imports.
The in-vitro diagnostics instruments market research report is one of a series of new reports that provides in-vitro diagnostics instruments market statistics, including in-vitro diagnostics instruments industry global market size, regional shares, competitors with a in-vitro diagnostics instruments market share, detailed in-vitro diagnostics instruments market segments, market trends and opportunities, and any further data you may need to thrive in the in-vitro diagnostics instruments industry. This in-vitro diagnostics instruments market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
In-vitro diagnostic instruments are medical devices used to analyze biological samples, such as blood, urine, or tissue, outside the human body. Their primary function is to detect, diagnose, monitor, and manage diseases or medical conditions by providing accurate and timely laboratory test results. These instruments aid clinical decision-making and support personalized patient care.
The primary product types of in-vitro diagnostic instruments include clinical chemistry, immunoassay, molecular diagnostics, hematology, microbiology, coagulation, and others. Clinical chemistry instruments are digital tools, often leveraging AI, to analyze blood, urine, and other body fluids, helping identify biochemical abnormalities, improve diagnostic accuracy, and guide treatment planning. These instruments are applied across multiple areas, including infectious diseases, cancer, cardiology, nephrology, and autoimmune disorders. They serve a diverse range of end users, including hospitals, diagnostic laboratories, academic and research institutes, point-of-care facilities, blood banks, and pharmaceutical and biotechnology companies.
The in-vitro diagnostics instruments market consists of sales of point-of-care testing devices, flow cytometry instruments, histopathology and cytology instruments, and molecular point-of-care systems. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 1-3 business days.
The in-vitro diagnostics instruments market size is expected to see rapid growth in the next few years. It will grow to $99.44 billion in 2030 at a compound annual growth rate (CAGR) of 10.3%. The growth in the forecast period can be attributed to technological advancements in molecular diagnostics, growth of personalized medicine, integration of AI in diagnostics, expansion of emerging markets healthcare, demand for home-based diagnostic devices. Major trends in the forecast period include point-of-care testing expansion, personalized diagnostics, rapid molecular testing adoption, remote patient monitoring integration, miniaturized lab instruments.
The rising prevalence of chronic and lifestyle related diseases is expected to enhance the growth of the in vitro diagnostics instruments market in the coming years. Chronic and lifestyle related diseases refer to long term health conditions primarily influenced by daily habits, behaviors, and environmental factors, such as heart disease, diabetes, obesity, and certain cancers. The incidence of these diseases is increasing due to sedentary lifestyles and unhealthy dietary habits. In vitro diagnostics instruments are experiencing higher demand as the growing burden of chronic and lifestyle related diseases encourages companies to adopt early detection and monitoring tools for improved disease management. For example, in 2024, according to the American Action Forum, a U.S. based non profit, center right think tank, chronic diseases remain a major public health concern in the United States, with nearly 60 percent of adults living with at least one condition, 40 percent managing multiple conditions, and prevalence expected to nearly double by 2050. Furthermore, the chronic disease treatment market is projected to reach approximately 38.02 billion dollars by 2034, up from 9.74 billion dollars in 2025. Therefore, the rising prevalence of chronic and lifestyle related diseases is enhancing the growth of the in vitro diagnostics instruments market.
Prominent companies operating in the in-vitro diagnostics instruments market are focusing on developing advanced technologies, such as digital polymerase chain reaction (dPCR) systems, to achieve highly precise and sensitive nucleic acid quantification for next-generation diagnostics. Digital polymerase chain reaction (dPCR) systems are sophisticated diagnostic instruments that quantify DNA or RNA molecules by dividing samples into thousands of individual reactions, allowing for exceptional accuracy and sensitivity in detection. For example, in September 2024, QIAGEN N.V., a Netherlands-based biotechnology company, introduced the QIAcuityDx Digital PCR System, expanding its dPCR portfolio into clinical diagnostics with a primary focus on oncology testing. This fully integrated and automated system is specifically designed for clinical use, featuring a cartridge-based workflow that minimizes manual handling. Equipped with automated analysis and reporting software, the QIAcuityDx enables rapid and precise detection of genetic biomarkers for cancer diagnosis and therapy monitoring, reducing operator involvement while ensuring reliable and reproducible results.
In January 2025, Fremman Ltd., a UK-based investment company, acquired a majority stake in DIESSE Diagnostica Senese S.p.A. for an undisclosed amount. Through this acquisition, Fremman Ltd aims to expand DIESSE Diagnostica Senese's international presence, strengthen its leadership in specialty in vitro diagnostics, and support ongoing innovation to advance global diagnostic capabilities and improve patient outcomes. DIESSE Diagnostica Senese S.p.A. is an Italy-based medical equipment company that provides in vitro diagnostic instruments.
Major companies operating in the in-vitro diagnostics instruments market are F. Hoffmann-La Roche Ltd, Danaher Corporation, Abbott Laboratories, Thermo Fisher Scientific, Siemens Healthineers AG, Becton Dickinson and Company, Sysmex Corporation, Bio-Rad Laboratories Inc, Agilent Technologies, Hologic Inc, Qiagen N.V., Illumina Inc, Ortho Clinical Diagnostics, Beckman Coulter Inc, Mindray Medical International Limited, Horiba Ltd, Randox Laboratories Ltd, DiaSorin S.p.A., Werfen S.A., Trinity Biotech plc.
North America was the largest region in the in-vitro diagnostics instruments market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the in-vitro diagnostics instruments market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the in-vitro diagnostics instruments market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Tariffs are impacting the in-vitro diagnostics instruments market by increasing costs of imported reagents, analyzers, and precision components, particularly affecting molecular diagnostics and clinical chemistry segments. Asia-Pacific manufacturing hubs such as China and India are most impacted, causing supply chain disruptions and higher device prices. However, tariffs are encouraging local manufacturing investments, which could improve domestic production capabilities and reduce long-term dependency on imports.
The in-vitro diagnostics instruments market research report is one of a series of new reports that provides in-vitro diagnostics instruments market statistics, including in-vitro diagnostics instruments industry global market size, regional shares, competitors with a in-vitro diagnostics instruments market share, detailed in-vitro diagnostics instruments market segments, market trends and opportunities, and any further data you may need to thrive in the in-vitro diagnostics instruments industry. This in-vitro diagnostics instruments market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
In-vitro diagnostic instruments are medical devices used to analyze biological samples, such as blood, urine, or tissue, outside the human body. Their primary function is to detect, diagnose, monitor, and manage diseases or medical conditions by providing accurate and timely laboratory test results. These instruments aid clinical decision-making and support personalized patient care.
The primary product types of in-vitro diagnostic instruments include clinical chemistry, immunoassay, molecular diagnostics, hematology, microbiology, coagulation, and others. Clinical chemistry instruments are digital tools, often leveraging AI, to analyze blood, urine, and other body fluids, helping identify biochemical abnormalities, improve diagnostic accuracy, and guide treatment planning. These instruments are applied across multiple areas, including infectious diseases, cancer, cardiology, nephrology, and autoimmune disorders. They serve a diverse range of end users, including hospitals, diagnostic laboratories, academic and research institutes, point-of-care facilities, blood banks, and pharmaceutical and biotechnology companies.
The in-vitro diagnostics instruments market consists of sales of point-of-care testing devices, flow cytometry instruments, histopathology and cytology instruments, and molecular point-of-care systems. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 1-3 business days.
Table of Contents
1. Executive Summary
2. in-Vitro Diagnostics Instruments Market Characteristics
3. in-Vitro Diagnostics Instruments Market Supply Chain Analysis
4. Global in-Vitro Diagnostics Instruments Market Trends and Strategies
5. in-Vitro Diagnostics Instruments Market Analysis of End Use Industries
7. Global in-Vitro Diagnostics Instruments Strategic Analysis Framework, Current Market Size, Market Comparisons and Growth Rate Analysis
8. Global in-Vitro Diagnostics Instruments Total Addressable Market (TAM) Analysis for the Market
9. in-Vitro Diagnostics Instruments Market Segmentation
10. in-Vitro Diagnostics Instruments Market Regional and Country Analysis
11. Asia-Pacific in-Vitro Diagnostics Instruments Market
12. China in-Vitro Diagnostics Instruments Market
13. India in-Vitro Diagnostics Instruments Market
14. Japan in-Vitro Diagnostics Instruments Market
15. Australia in-Vitro Diagnostics Instruments Market
16. Indonesia in-Vitro Diagnostics Instruments Market
17. South Korea in-Vitro Diagnostics Instruments Market
18. Taiwan in-Vitro Diagnostics Instruments Market
19. South East Asia in-Vitro Diagnostics Instruments Market
20. Western Europe in-Vitro Diagnostics Instruments Market
21. UK in-Vitro Diagnostics Instruments Market
22. Germany in-Vitro Diagnostics Instruments Market
23. France in-Vitro Diagnostics Instruments Market
24. Italy in-Vitro Diagnostics Instruments Market
25. Spain in-Vitro Diagnostics Instruments Market
26. Eastern Europe in-Vitro Diagnostics Instruments Market
27. Russia in-Vitro Diagnostics Instruments Market
28. North America in-Vitro Diagnostics Instruments Market
29. USA in-Vitro Diagnostics Instruments Market
30. Canada in-Vitro Diagnostics Instruments Market
31. South America in-Vitro Diagnostics Instruments Market
32. Brazil in-Vitro Diagnostics Instruments Market
33. Middle East in-Vitro Diagnostics Instruments Market
34. Africa in-Vitro Diagnostics Instruments Market
36. in-Vitro Diagnostics Instruments Market Competitive Landscape and Company Profiles
37. in-Vitro Diagnostics Instruments Market Other Major and Innovative Companies
40. in-Vitro Diagnostics Instruments Market High Potential Countries, Segments and Strategies
41. Appendix
List of Tables
Executive Summary
In-Vitro Diagnostics Instruments Market Global Report 2026 provides strategists, marketers and senior management with the critical information they need to assess the market.This report focuses in-vitro diagnostics instruments market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase:
- Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
- Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, inflation and interest rate fluctuations, and evolving regulatory landscapes.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on end user analysis.
- Benchmark performance against key competitors based on market share, innovation, and brand strength.
- Evaluate the total addressable market (TAM) and market attractiveness scoring to measure market potential.
- Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
- Report will be updated with the latest data and delivered to you along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Description
Where is the largest and fastest growing market for in-vitro diagnostics instruments? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The in-vitro diagnostics instruments market global report answers all these questions and many more.The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market. This section also examines key products and services offered in the market, evaluates brand-level differentiation, compares product features, and highlights major innovation and product development trends.
- The supply chain analysis section provides an overview of the entire value chain, including key raw materials, resources, and supplier analysis. It also provides a list competitor at each level of the supply chain.
- The updated trends and strategies section analyses the shape of the market as it evolves and highlights emerging technology trends such as digital transformation, automation, sustainability initiatives, and AI-driven innovation. It suggests how companies can leverage these advancements to strengthen their market position and achieve competitive differentiation.
- The regulatory and investment landscape section provides an overview of the key regulatory frameworks, regularity bodies, associations, and government policies influencing the market. It also examines major investment flows, incentives, and funding trends shaping industry growth and innovation.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
- The total addressable market (TAM) analysis section defines and estimates the market potential compares it with the current market size, and provides strategic insights and growth opportunities based on this evaluation.
- The market attractiveness scoring section evaluates the market based on a quantitative scoring framework that considers growth potential, competitive dynamics, strategic fit, and risk profile. It also provides interpretive insights and strategic implications for decision-makers.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
- Expanded geographical coverage includes Taiwan and Southeast Asia, reflecting recent supply chain realignments and manufacturing shifts in the region. This section analyzes how these markets are becoming increasingly important hubs in the global value chain.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The company scoring matrix section evaluates and ranks leading companies based on a multi-parameter framework that includes market share or revenues, product innovation, and brand recognition.
Report Scope
Markets Covered:
1) By Product Type: Clinical Chemistry; Immunoassay; Molecular Diagnostics; Hematology; Microbiology; Coagulation; Other Product Types2) By Application: Infectious Diseases; Cancer; Cardiology; Nephrology; Autoimmune Diseases; Other Applications
3) By End User: Hospitals And Diagnostic Laboratories; Academic And Research Institutes; Point-Of-Care Settings; Blood Banks; Pharmaceutical And Biotechnology Companies; Other Healthcare Facilities
Subsegments:
1) By Clinical Chemistry: Automated Clinical Chemistry Analyzers; Semi-Automated Clinical Chemistry Analyzers; Point-Of-Care Clinical Chemistry Devices2) By Immunoassay: Enzyme-Linked Immunosorbent Assay (ELISA) Systems; Chemiluminescence Immunoassay (CLIA) Analyzers; Radioimmunoassay (RIA) Systems
3) By Molecular Diagnostics: Polymerase Chain Reaction (PCR) Systems; Next-Generation Sequencing (NGS) Platforms; Deoxyribonucleic Acid Microarrays; Isothermal Amplification Devices
4) By Hematology: Automated Hematology Analyzers; Manual Hematology Analyzers; Hemostasis Analyzers; Coagulation Analyzers
5) By Microbiology: Microbial Identification Systems; Antibiotic Susceptibility Testing (AST) Systems; Blood Culture Systems; Automated Microbial Analyzers.
6) By Coagulation: Coagulometers; Platelet Function Analyzers; Thromboelastography (TEG) Systems; Point-Of-Care Coagulation Devices
7) By Other Product Types: Point-Of-Care Diagnostic Devices; Miscellaneous Laboratory Instruments
Companies Mentioned: F. Hoffmann-La Roche Ltd; Danaher Corporation; Abbott Laboratories; Thermo Fisher Scientific; Siemens Healthineers AG; Becton Dickinson and Company; Sysmex Corporation; Bio-Rad Laboratories Inc; Agilent Technologies; Hologic Inc; Qiagen N.V.; Illumina Inc; Ortho Clinical Diagnostics; Beckman Coulter Inc; Mindray Medical International Limited; Horiba Ltd; Randox Laboratories Ltd; DiaSorin S.p.A.; Werfen S.A.; Trinity Biotech plc
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Taiwan; Russia; South Korea; UK; USA; Canada; Italy; Spain
Regions: Asia-Pacific; South East Asia; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita.
Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: Word, PDF or Interactive Report + Excel Dashboard
Added Benefits:
- Bi-Annual Data Update
- Customisation
- Expert Consultant Support
Companies Mentioned
The companies featured in this In-Vitro Diagnostics Instruments market report include:- F. Hoffmann-La Roche Ltd
- Danaher Corporation
- Abbott Laboratories
- Thermo Fisher Scientific
- Siemens Healthineers AG
- Becton Dickinson and Company
- Sysmex Corporation
- Bio-Rad Laboratories Inc
- Agilent Technologies
- Hologic Inc
- Qiagen N.V.
- Illumina Inc
- Ortho Clinical Diagnostics
- Beckman Coulter Inc
- Mindray Medical International Limited
- Horiba Ltd
- Randox Laboratories Ltd
- DiaSorin S.p.A.
- Werfen S.A.
- Trinity Biotech plc
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 250 |
| Published | February 2026 |
| Forecast Period | 2026 - 2030 |
| Estimated Market Value ( USD | $ 67.18 Billion |
| Forecasted Market Value ( USD | $ 99.44 Billion |
| Compound Annual Growth Rate | 10.3% |
| Regions Covered | Global |
| No. of Companies Mentioned | 21 |
